Association of Tumor-infiltrating Lymphocytes With Recurrence Score in Hormone Receptor-positive/HER2-negative Breast Cancer: Analysis of Four Prospective Studies

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

(2022) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer

(2022) Barbara Pistilli et al.   American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer

(2022) Mariya Rozenblit et al.   BREAST CANCER RESEARCH AND TREATMENT

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

(2021) Thomas Bachelot et al.   NATURE MEDICINE

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications

(2021) Maria Vittoria Dieci et al.   Cells

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

(2021) Francesco Cognetti et al.   npj Breast Cancer

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

(2021) Lajos Pusztai et al.   CANCER CELL

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial

(2021) Maria Vittoria Dieci et al.   CLINICAL CANCER RESEARCH

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

(2021) Kevin Kalinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

(2020) Rita Nanda et al.   JAMA Oncology

Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study

(2020) Alberto Zambelli et al.   BREAST

Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer

(2020) C. Criscitiello et al.   BREAST CANCER RESEARCH AND TREATMENT

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

(2020) Stephen R. D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

(2020) Sara M. Tolaney et al.   JAMA Oncology

Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

(2019) Yukie Fujimoto et al.   Breast Cancer

Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study

(2019) Maria Vittoria Dieci et al.   ONCOLOGIST

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer

(2018) Sung Gwe Ahn et al.   BMC CANCER

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

(2018) Carsten Denkert et al.   LANCET ONCOLOGY

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer

(2017) Maria Vittoria Dieci et al.   ONCOLOGIST

The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

(2016) Maria Vittoria Dieci et al.   CANCER TREATMENT REVIEWS

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer

(2015) Satu Tiainen et al.   HISTOPATHOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis

(2014) Zhong-Yu Yuan et al.   OncoTargets and Therapy

Tumor-infiltrating lymphocytes in breast cancer

(2014) Yasmin Issa-Nummer et al.   OncoImmunology

Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

(2012) Aleix Prat et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-infiltrating macrophages and clinical outcome in breast cancer

(2011) S M A Mahmoud et al.   JOURNAL OF CLINICAL PATHOLOGY

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

(2008) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY